BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3264133)

  • 1. Antimicrobial susceptibilities of southern African isolates of Haemophilus ducreyi.
    Dangor Y; Miller SD; Exposto Fda L; Koornhof HJ
    Antimicrob Agents Chemother; 1988 Sep; 32(9):1458-60. PubMed ID: 3264133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibility of 103 strains of Haemophilus ducreyi isolated in Johannesburg.
    Bilgeri YR; Ballard RC; Duncan MO; Mauff AC; Koornhof HJ
    Antimicrob Agents Chemother; 1982 Oct; 22(4):686-8. PubMed ID: 6983858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro susceptibility of thirty strains of Haemophilus ducreyi to several antibiotics including six cephalosporins.
    Sanson-Le Pors MJ; Casin I; Ortenberg M; Perol Y
    J Antimicrob Chemother; 1983 Mar; 11(3):271-80. PubMed ID: 6601649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility of Haemophilus ducreyi.
    Hammond GW; Lian CJ; Wilt JC; Ronald AR
    Antimicrob Agents Chemother; 1978 Apr; 13(4):608-12. PubMed ID: 307364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic susceptibilities and plasmid profiles of Haemophilus ducreyi isolates from southern Africa.
    Abeck D; Johnson AP; Dangor Y; Ballard RC
    J Antimicrob Chemother; 1988 Oct; 22(4):437-44. PubMed ID: 3264554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of antimicrobial susceptibility patterns of fifty-seven strains of Haemophilus ducreyi isolated in Amsterdam from 1978 to 1985.
    Sturm AW
    J Antimicrob Chemother; 1987 Feb; 19(2):187-91. PubMed ID: 3494720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of Haemophilus ducreyi resistance to trimethoprim-sulfamethoxazole in Rwanda.
    Van Dyck E; Bogaerts J; Smet H; Tello WM; Mukantabana V; Piot P
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1647-8. PubMed ID: 7979300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between in vitro antimicrobial susceptibilities and beta-lactamase plasmid contents of isolates of Haemophilus ducreyi from the United States.
    Motley M; Sarafian SK; Knapp JS; Zaidi AA; Schmid G
    Antimicrob Agents Chemother; 1992 Aug; 36(8):1639-43. PubMed ID: 1416845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of 40 Haemophilus ducreyi strains to 34 antimicrobial products.
    Slootmans L; Vanden Berghe DA; Van Dyck E; Piot P
    Antimicrob Agents Chemother; 1983 Oct; 24(4):564-7. PubMed ID: 6606394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the in vitro activities of various parenteral and oral antimicrobial agents against endemic Haemophilus ducreyi.
    Aldridge KE; Cammarata C; Martin DH
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1986-8. PubMed ID: 8239617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Etest with agar dilution for antimicrobial susceptibility testing of Haemophilus ducreyi.
    LagergÄrd T; Frisk A; Trollfors B
    J Antimicrob Chemother; 1996 Nov; 38(5):849-52. PubMed ID: 8961054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance of Haemophilus ducreyi.
    Rutanarugsa A; Vorachit M; Polnikorn N; Jayanetra P
    Southeast Asian J Trop Med Public Health; 1990 Jun; 21(2):185-93. PubMed ID: 2237585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activities of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi.
    Sanson-Le Pors MJ; Casin IM; Thebault MC; Arlet G; Perol Y
    Antimicrob Agents Chemother; 1986 Sep; 30(3):512-3. PubMed ID: 2946262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibilities of strains of Neisseria gonorrhoeae in Bangkok, Thailand: 1994-1995.
    Knapp JS; Wongba C; Limpakarnjanarat K; Young NL; Parekh MC; Neal SW; Buatiang A; Chitwarakorn A; Mastro TD
    Sex Transm Dis; 1997 Mar; 24(3):142-8. PubMed ID: 9132980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibilities of isolates of Haemophilus ducreyi from Thailand and the United States to currently recommended and newer agents for treatment of chancroid.
    Knapp JS; Back AF; Babst AF; Taylor D; Rice RJ
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1552-5. PubMed ID: 8363390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility and characterization of outer membrane proteins of Haemophilus ducreyi isolated in Thailand.
    Taylor DN; Echeverria P; Hanchalay S; Pitarangsi C; Slootmans L; Piot P
    J Clin Microbiol; 1985 Mar; 21(3):442-4. PubMed ID: 3872313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of Haemophilus ducreyi. A study.
    Sng EH; Lim AL; Rajan VS; Goh AJ
    Br J Vener Dis; 1982 Aug; 58(4):239-42. PubMed ID: 6980682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemophilus ducreyi is resistant to human antimicrobial peptides.
    Mount KL; Townsend CA; Bauer ME
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3391-3. PubMed ID: 17620373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of Haemophilus ducreyi to several antibiotics.
    Ismaeel NA
    Microbios; 1993; 74(299):103-9. PubMed ID: 8361391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative in-vitro activity of twelve 4-quinolone antimicrobials against Haemophilus ducreyi.
    Wall RA; Mabey DC; Bello CS; Felmingham D
    J Antimicrob Chemother; 1985 Aug; 16(2):165-8. PubMed ID: 3877717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.